Navigation Links
U.S. Army and Navy Purchase Over 10,000 New Beretta M9 Pistols
Date:9/22/2007

ACCOKEEK, Md., Sept. 10 /PRNewswire/ -- Beretta U.S.A. Corp. announced today the receipt of purchase orders from the U.S. Army and U.S. Navy for a total of 10,576 M9 pistols (5,969 for the Army, 4,607 for the Navy). The purchase orders were issued against a multi-year contract between Beretta U.S.A. and the U.S. Army, which serves as executive purchasing agent of the M9 pistol for all branches of the U.S. Armed Forces.

"We are always honored to be given the opportunity to serve the U.S. Armed Forces by supplying the Beretta M9 pistol," noted Jeff Reh, Vice-General Manager for Beretta U.S.A. Corp. "The Beretta M9 pistol remains the most reliable and well-tested handgun in the U.S. military inventory, with tests resulting in an average of only one malfunction every 20,500 rounds fired." Beretta U.S.A. Corp., manufacturer of the Beretta M9 pistol, employs over 330 employees and manufactures the sidearm at its factory in Accokeek, Maryland.

Beretta U.S.A. Corp. has supplied the Beretta M9 pistol as the standard sidearm for the U.S. Armed Forces since 1985.

In 2005, Beretta U.S.A. Corp. received 13 contracts for M9 pistols and component parts from the U.S. Army and U.S. Marine Corps. Many of the U.S. Army contracts were multi-year contracts lasting five years, from which over 31 million dollars in purchase orders have since been issued to Beretta U.S.A. Corp.

Beretta, established in 1526, is the oldest industrial dynasty in the world tracing its roots through 16 generations of continuous family ownership. Firearms bearing the Beretta name have been sold for almost 500 years. Beretta USA Corp. was founded in 1977 and supplies the standard sidearm to the U.S. Armed Forces. Today Beretta manufactures, distributes and markets a complete line of firearms, accessories and apparel. Beretta also owns and operates six retail Beretta Gallery stores worldwide. For additional information visit http://ww
'/>"/>

SOURCE Beretta U.S.A. Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. ... human interface solutions, today announced that Huawei has ... touchscreen solution for its stylish smartwatch. Huawei chose ... proven reliability, low power and highly responsive human ... finger. Huawei designers also required a classic round ...
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2015.  Revenue ... decrease of 33% compared to $6.8 million in the same ... 2015 was $0.3 million, or $0.01 per diluted share, which ... the same period a year ago.  Lower ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... Looking into the brain is yielding vital clues to ... being presented today at the Seventh International Conference on ... held at 12:15 p.m., Thursday, June 7, have helped ... treatment of the disease. , The first study, presented ...
... crops may contribute to increased productivity in sustainable agriculture, ... 8 issue of the journal Science. The study ... field experiments all over the world, involving corn and ... insecticidal properties. The research was conducted by scientists ...
... In a way, nanotubes are nature’s smallest candles. , These ... so small that it takes about 100,000 laid side-by-side to ... last five years, scientists have discovered that some individual nanotubes ... in light. Some glow brightly. Others glow dimly. Some glow ...
Cached Biology News:Brain holds clues to bipolar disorder 2New study finds genetically engineered crops could play a role in sustainable agriculture 2Brightening prospects of using fluorescent nanotubes in medical applications 2Brightening prospects of using fluorescent nanotubes in medical applications 3
(Date:7/27/2015)... July 27, 2015 IDEXX Laboratories, Inc. (NASDAQ: ... clinics have submitted over 100,000 specimens to IDEXX Reference ... the first 10 days since the breakthrough kidney function ... is a leading cause of suffering and death in ... are consistent with generally accepted kidney disease prevalence data ...
(Date:7/24/2015)... (PRWEB) , ... July 24, 2015 , ... VetStem Biopharma, ... Center in support of stem cell therapy training and clinical opportunities. , “We are ... opportunity to veterinarians in the San Diego area. Stem cell therapy is an established ...
(Date:7/24/2015)... SAN FRANCISCO , July 24, 2015 ... is expected to reach USD 27.8 billion by ... 2015 to 2022, according to a new study by ... genomic sequencing methodologies is expected to result in significant ... is expected to augment adoption and usage rates of ...
(Date:7/23/2015)... ... July 23, 2015 , ... Science and technology continue ... new drug therapies and devices – according to Susan Chang, MD, director of the ... on how science and new technology are impacting the development of new treatments and ...
Breaking Biology Technology:Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3
... Company to Hold a Conference Call Tomorrow (Tuesday) at 8:30 am ... ... September 10 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ; LSE: XTL; ... of Bicifadine - a serotonin,and norepinephrine reuptake inhibitor (SNRI) - for ...
... LONDON, Sept. 7 Chiltern, a leading global ... Richard Schulz,Chiltern,s Country Manager for the Czech Republic, ... The award ceremony was held in,London,s historic Gibson ... peers by a panel of judges who,reviewed his ...
... On Thursday, October,18, 2007, Wyeth (NYSE: WYE ) ... Company will hold a one-hour conference call with,research analysts ... Interested,investors and others may listen to the call live ... may be accessed by visiting our website,at http://www.wyeth.com ...
Cached Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... atoms at the 9, 10, 12, and 13 ... internal standard for the quantification of 9(S)-HODE by ... the lipoxygenation of linoleic acid in both plants ... plaques, as an esterified component of membrane phospholipids ...
... 9(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 9(S)-HODE is produced by the lipoxygenation of ... has been detected in atherosclerotic plaques, as an ...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: